Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Latest Financial Report
Interim Report Q4 2022 incl. Full Year Report, January 26
PDF | AudioCast | Presentation
Latest presentations
Analyst reports
Investment themes
Latest CEO Comments
JANUARY 26, 2023
"Well positioned to capture new market opportunities and reach profitability "
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Invitation to presentation of Orexo´s Interim Report Q4 2022 incl. Full Year Report
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
Edward Kim, M.D., Chief Medical Officer: “I joined Orexo to make a difference in the lives of people suffering from opioid use disorder”
Key financial figures
Group net revenue
624.3 MSEK
Last Twelve Months, Q122-Q422
Group EBITDA
-115.2 MSEK
Last Twelve Months, Q122-Q422
US Pharma segment EBIT
308.4 MSEK
Last Twelve Months, Q122-Q422
Cash position
359.1 MSEK
Q422
